Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Stemline Therapeutics Inc Announces Closing of Initial Public Offering


Thursday, 31 Jan 2013 04:08pm EST 

Stemline Therapeutics Inc announced the closing of its previously announced initial public offering of 3,815,291 shares of common stock, including the exercise in full of the over-allotment option covering 497,647 shares, at a public offering price of $10.00 per share. The gross proceeds to Stemline from the offering, including the exercise of the over-allotment option, were $38,152,910, before deducting underwriting discounts and commissions and other offering expenses payable by Stemline. Aegis Capital Corp. acted as sole book-running manager for the offering. Feltl and Company, Inc. and Sunrise Securities Corp. acted as co-managers for the offering. 

Company Quote

11.72
-1.07 -8.37%
22 Sep 2014